antidepressant/stroke

TECHNICAL FIELD This invention relates generally to the discovery of pro-neurogenic compounds capable of promoting neurogenesis and/or reducing neuronal cell death, more particularly use of such compounds as antidepressant agents. BACKGROUND It is now accepted that the adult vertebrate brain fosters

TECHNICAL FIELD This invention relates generally to the discovery of pro-neurogenic compounds capable of promoting neurogenesis and/or reducing neuronal cell death, more particularly use of such compounds as antidepressant agents. BACKGROUND It is now accepted that the adult vertebrate brain fosters

TECHNICAL FIELD This invention relates generally to the discovery of pro-neurogenic compounds capable of promoting neurogenesis and/or reducing neuronal cell death, more particularly use of such compounds as antidepressant agents. BACKGROUND It is now accepted that the adult vertebrate brain fosters

The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds which have affinity for 5-HT.sub.1A receptors and which inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their

FIELD OF THE INVENTION The invention relates to the field of bioorganic chemistry, namely to novel substituted dipeptides that are mimetics of the neurotrophic factors, which can be useful as pharmaceutical agents for the regulation of growth, differentiation, survival and programmed neuronal cell

The present application relates to new uses of 5-HT.sub.6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT.sub.6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with a second therapeutic

This application is a 371 of International Application No. PCT/EP2008/067225, filed 10 Dec. 2008, which claims the priority of GB Application Nos. 072428.1, filed 12 Dec. 2007, and 0724285.2, filed 12 Dec. 2007, which are incorporated herein in their entireties. The present application relates to

FIELD OF THE INVENTION The present invention relates to therapeutically active quinolinic sulfide derivatives acting as potent and specific antagonists of excitatory amino acids, to a process for preparation and to their use in treatment in neurological disorders. Particularly, the compounds